Format

Send to

Choose Destination
J Antimicrob Chemother. 2007 Jul;60(1):159-61. Epub 2007 Apr 21.

In vitro and in vivo antibacterial evaluation of DRF 8417, a new oxazolidinone.

Author information

1
Anti-infective Group, Discovery Research, Dr Reddy's Laboratories Ltd, Miyapur, Hyderabad 500 049, India. sreenivaskandepu@drreddys.com

Abstract

OBJECTIVES AND METHODS:

DRF 8417, a novel oxazolidinone, has been evaluated against Gram-positive and fastidious Gram-negative bacteria. In vitro activity of DRF 8417 was determined by broth microdilution method and in vivo efficacy studies were carried out in different murine systemic infection models.

RESULTS:

DRF 8417 exhibited potent activity against Gram-positive pathogens with MIC(50) and MIC(90) values ranging from 0.06 to 1 mg/L. MICs against Haemophilus influenzae and Moraxella catarrhalis were one to two dilutions lower than those of linezolid. The in vivo efficacy, by oral route, in different susceptible and resistant Gram-positive systemic bacterial infection models ranged from 2.0 to 2.9 mg/kg.

CONCLUSIONS:

These studies displayed the excellent in vitro and in vivo activity of DRF 8417 against Gram-positive pathogens and lower MICs when compared with linezolid against H. influenzae and M. catarrhalis.

PMID:
17449889
DOI:
10.1093/jac/dkm116
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center